Hodgkin disease survival in Europe and the U.S.: Prognostic significance of morphologic groups

Cancer

Volumn 107, Issue 2, 2006, Pages 352-360

  Allemani, Claudia ^a   Sant, Milena ^a   De Angelis, Roberta ^b   Marcos Gragera, Rafael ^c   Coebergh, Jan Willem ^d   Oberaigner, W ^e   Storm, H H ^f   Aareleid, T ^g   Jechova, M ^h   Rousarova, M ^h   Hakulinen, T ⁱ   Hedelin, G ^j   Tron, I ^k   Le Gall, E ^k   Launoy, G ^l   Mace Lesec'h, J ^m   Faivre, J ⁿ   Chaplain, G ^o   Carli, P M ^p   Danzon, A ^q   Tretarre, B ^r   Colonna, M ^s   Lacour, B ^t   Raverdy, N ^u   Berger, C ^v   Freycon, B ^v   Grosclaude, P ^w   Esteve, J ^x   Kaatsch, P ^y   Ziegler, H ^z   Holzel, D ^aa   Fritschle, G Schubert ^aa   Tryggvadottir, L ^ab   Berrino, F ^ac   Baili, P ^a   Ciccolallo, L ^a   Crosignani, P ^a   Gatta, G ^a   Micheli, A ^a   Taussig, E ^a   Sowe, S ^a   Ferretti, S ^ad   Conti, E ^ae   Vercelli, M ^af   Quaglia, A ^af   Pannelli, F ^ag   Federico, M ^ah   Artioli, M E ^ah   Ponz De Leon, M ^ai   Benatti, P ^ai   De Lisi, V ^aj   Servente, L ^aj   Zanetti, R ^ak   Patriarca, S ^ak   Magnani, C ^al   Pastore, G ^al   Gafa, L ^am   Tumino, R ^am   Falcini, F ^an   Budroni, M ^ao   Paci, E ^ap   Crocetti, E ^ap   Zambon, P ^aq   Guzzinati, S ^aq   Capocaccia, R ^b   Carrani, E ^b   Roazzi, P ^b   Santaquilani, M ^b   Tavilla, A ^b   Valente, F ^b   Verdecchia, A ^b   Delmas, M ^ar   Langmark, F ^as   Andersen, A ^as   Rachtan, J ^at   Bielska Lasota, M ^au   Wronkowski, Z ^au   Plesko, I ^av   Obsitnikova, A ^av   Pompe Kirn, V ^aw   Izarzugaza, I ^ax   Martinez Garcia, C ^ay   Garau, I ^az   Navarro, C ^ba   Chirlaque, M D ^ba   Ardanaz, E ^bb   Moreno, C ^bb   Galceran, J ^bc   Torrella, A ^bd   Peris Bonet, R ^be   Barlow, L ^bf   Moller, T ^bf   Jundt, G ^bg   Lutz, J M ^bh   Bouchardy, C ^bh   Van Der Does Van Den Berg, A ^bi   Visser, O ^bj   Godward, S ^bk   Coleman, M P ^bl   Williams, E M I ^bm   Forman, D ^bn   Quinn, M J ^bo   Roche, M ^bp   Edwards, S ^bp   Stiller, C ^bq   Verne, J ^ac   Moller, H ^br   Bell, J ^br   Botha, J L ^bs   Lawrence, G ^bt   Black, R ^bu   Steward, J A ^bv   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d Eindhoven Cancer Registry   (Netherlands)

^e Tyrol Cancer Registry   (Austria)

^f DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^g Estonian Cancer Registry   (Estonia)

^h Institute of Health Information and Statistics of the Czech Republic   (Czech Republic)

ⁱ FINNISH CANCER REGISTRY   (Finland)

^j Cancer Registry of Bas Rhin   (France)

^k Bretagne Childhood Cancer Registry   (France)

^l Calvados Digestive Cancer Registry   (France)

^m Calvados General Cancer Registry   (France)

ⁿ ote d'Or Digestive Cancer Registry   (France)

^o Côte d'Or Gynaecological Cancer Registry   (France)

^p Cote d'Or Malignant Haemopathies Registry ^*  (France)

^q Doubs Cancer Registry   (France)

^r Herault Cancer Registry   (France)

^s Isere Cancer Registry   (France)

^t Lorraine Childhood Cancer Registry   (France)

^u Somme Cancer Registry   (France)

^v Rhone Alpes Childhood Registry   (France)

^w Tarn Cancer Registry   (France)

^x UNIVERSITÉ DE LYON   (France)

^y German Childhood Cancer Registry   (Germany)

^z Saarland Cancer Registry   (Germany)

^aa Munich Cancer Registry   (Germany)

^ab ICELANDIC CANCER REGISTRY   (Iceland)

^ac Lombardy Cancer Registry ^*  (United Kingdom)

^ad Ferrara Cancer Registry   (Italy)

^ae Latina Cancer Registry   (Italy)

^af Department of Oncology Biology and Genetics   (Italy)

^ag Macerata Cancer Registry   (Italy)

^ah MODENA CANCER REGISTRY   (Italy)

^ai Modena Colorectal Cancer Registry ^*  (Italy)

^aj PARMA CANCER REGISTRY   (Italy)

^ak Piedmont Cancer Registry   (Italy)

^al Piedmont Childhood Cancer Registry   (Italy)

^am Ragusa Cancer Registry   (Italy)

^an Romagna Cancer Registry   (Italy)

^ao Sassari Cancer Registry   (Italy)

^ap Tuscan Cancer Registry   (Italy)

^aq Venetian Cancer Registry   (Italy)

^ar Malta National Cancer Registry   (Malta)

^as CANCER REGISTRY OF NORWAY   (Norway)

^at Cracow Cancer Registry   (Poland)

^au INSTITUTE OF ONCOLOGY   (Poland)

^av National Cancer Registry of   (Slovakia)

^aw INSTITUTE OF ONCOLOGY   (Slovenia)

^ax Basque Country Cancer Registry   (Spain)

^ay Granada Cancer Registry   (Spain)

^az Mallorca Cancer Registry   (Spain)

^ba Murcia Cancer Registry   (Spain)

^bb Navarra Cancer Registry   (Spain)

^bc Tarragona Cancer Registry   (Spain)

^bd Childhood Tumor Registry of Valencia   (Spain)

^be National Registry of Childhood Tumours   (Spain)

^bf Cancer Registry of Sweden   (Sweden)

^bg Cancer Registry of Basel   (Switzerland)

^bh GENEVA CANCER REGISTRY   (Switzerland)

^bi Dutch Hildhood Oncology Group   (Netherlands)

^bj Cancer Center Amsterdam   (Netherlands)

^bk East Anglian Cancer Registry   (United Kingdom)

^bl LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^bm Merseyside and Cheshire Cancer Registry   (United Kingdom)

^bn OFFICE FOR NATIONAL STATISTICS   (United Kingdom)

^bo OFFICE FOR NATIONAL STATISTICS   (United Kingdom)

^bp UNIVERSITY OF OXFORD   (United Kingdom)

^bq Childhood Cancer Research Group   (United Kingdom)

^br Thames Cancer Registry   (United Kingdom)

^bs Trent Cancer Registry   (United Kingdom)

^bt W Midlands Cancer Intelligence Unit   (United Kingdom)

^bu Scottish Cancer Intelligence Unit   (United Kingdom)

^bv Welsh Cancer Intelligence and Surveillance Unit   (United Kingdom)

more..

Author keywords

Europe; Hodgkin disease; Morphology; Population cancer registries; Relative survival; U.S.

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; CHILD; EUROPE; FEMALE; GEOGRAPHIC DISTRIBUTION; HODGKIN DISEASE; HUMAN; INFANT; LYMPHOCYTE DEPLETION HODGKIN LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIXED CELLULARITY HODGKIN LYMPHOMA; MORPHOLOGY; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; EUROPE; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; REGISTRIES; SEER PROGRAM; UNITED STATES;

EID: 33745860068     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21995     Document Type: Article

References (35)

1. Sant M, Aareleid T, Berrino F, et al., EUROCARE-3: survival of cancer patients diagnosed 1990-1994-results and commentary. Ann Oncol. 2003;14(Supp 5):61-118.
2. De Vita VT, Serpick A, Carbone PP. Combination chemotherapy in the treatment of Hodgkin's disease. Ann Intern Med. 1970;73:881-895.
3. U.S. Department of Health and Human Services. National Cancer Institute, Surveillance, Epidemiology and End Results Program. SEER cancer statistics review, 1973-1999 [data set on CD ROM]. Bethesda: U.S. Department of Health and Human Services, 2001.
4. Jaffe ES, Harris LN, Stein H, Vatdiman JW. Tumours of haematopoietic and lymphoid tissues. WHO classification of tumours. Pathology and genetics. Lyon: IARC Press, 2001:240-253.
5. Percy C, Van Holten V, Muir C. International Classification of Diseases for Oncology. 2nd ed. Geneva: World Health Organization, 1990.
6. Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology. 3rd ed. Geneva: World Health Organization, 2000.
7. Dielh V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol. 1999;17:776-783.
8. Lukes R, Butler J, Hicks E. Natural history of Hodgkin's disease as related to its pathological picture. Cancer. 1966;19:317-344.
9. Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics. 1982;38:933-942.
10. Greenwood M. The errors of sampling of the survivorship table. Reports on public health and medical subjects, vol33. London: Her Majesty's Stationery Office, 1926.
11. Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med. 2004;23:51-64.
12. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease: international prognostic factors project on advanced Hodgkin's disease. N Engl J Med. 1998;339:1506-1514.
13. Gough J. Hodgkin's disease: a correlation of histopathology with survival. Int J Cancer. 1970;5:273-281.
14. Keller AR, Kaplan HS, Lukes RJ, Rappaport H. Correlation of histopathology with other prognostic indicators in Hodgkin's disease. Cancer. 1968;22:487-499.
15. Clarke CA, Glaser SL, Prehn AW. Age-specific survival after Hodgkin's disease in a population-based cohort (United States). Cancer Causes Control. 2001;12:803-812.
16. Van Spronsen DJ, Dijkema IM, Vrints LW, et al. Improved survival of Hodgkiris patients in South-East Netherlands since 1972. Eur J Cancer. 1997;33:436-441.
17. Berrino F, Sant M, Verdecchia A, Capocaccia R, Hakulinen T, Esteve J. Survival of cancer patients in Europe. The EUROCARE Study. Lyon: IARC Scientific Publication No. 132, 1995.
18. Sant M. Reliable data on stage distribution are essential. BMJ. 1999;319:1572.
19. Shimabukuro-Vornhagen A, Haverkamp H, Engert A, et al. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials. J Clin Oncol. 2005;23:5739-5745.
20. Glaser SL, Dorfman RF, Clarke CA. Expert review of the diagnosis and histologic classification of Hodgkin disease in a population-based cancer registry. Cancer. 2001;92:218-224.
21. Maudsley G, Williams EM. "Inaccuracy" in death certification-where are we now? J Public Health Med. 1996;18:59-66.
22. Reid DW, Hendrick VJ, Aitken TC, Berrill WT, Stenton SC, Hendrick DJ. Age-dependent inaccuracy of asthma death certification in Northern England, 1991-1992. Eur Respir J. 1998;12(5):1079-1083.
23. Arbyn M, Geys H. Trend of cervical cancer mortality in Belgium (1954-1994): tentative solution for the certification problem of unspecified uterine cancer. Int J Cancer. 2002;102:649-654.
24. Erdkamp FL, Breed WP, Bosch LJ, Wijnen JT, Blijham GB. Hodgkin disease in the elderly. A registry-based analysis. Cancer. 1992;5:830-834.
25. Wedelin C, Bjorkholm M, Biberfeld P, Holm G, Johansson B, Mellstedt H. Prognostic factors in Hodgkin's disease with special reference to age. Cancer. 1984;53:1202-1208.
26. Armstrong AA, Alexander FE, Cartwright R, et al. Epstein-Barr virus and Hodgkin's disease: further evidence for the three disease hypothesis. Leukemia. 1998;12:1272-1276.
27. Ginaldi L, De Martinis M, D'Ostilio A, Marini L, Loreto MF, Quaglino D. The immune system in the elderly: III. Innate immunity. Immunol Res. 1999;20:117.
28. Van Spronsen DJ, Janssen-Heijnen ML, Lemmens VE, Peters WG, Coebergh JW. Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry. Eur J Cancer. 2005;41:1051-1057.
29. Forsyth PD, Bessell EM, Moloney AJ, Leach IH, Davies JM, Fletcher J. Hodgkin's disease in patients older than 70 years of age: a registry-based analysis. Eur J Cancer. 1997;33:1638-1642.
30. Levis A, Anselmo AP, Ambrosetti A, et al. VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol. 2004;15:123-128.
31. Yung L, Linch D. Hodgkin's lymphoma. Lancet. 2003;361:943-951.
32. MacMahon B. Epidemiology of Hodgkin's disease. Cancer Res. 1996;26:1189-1200.
33. Klimm B, Reineke T, Haverkamp H, et al. Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. J Clin Oncol. 2005;23:8003-8011.
34. Ranson MR, Radford JA, Swindell R, et al. An analysis of prognostic factors in Stage III and IV Hodgkin's disease treated at a single centre with MVPP. Ann Oncol. 1991;2:423-429.
35. Bonadonna G, Viviani S, Bonfante V. Linfomi maligni. In: Bonadonna G, Robustelli della Cuna G, Valagussa P, editors. Medicina Oncologica. 7th ed. Milan: Masson, 2003:1275-1329.